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Poster Session I 7110.6 days. Conclusions: Despite known dismal prognosis, 3 out of
the 5 patients treated in our center are well at a follow-up of more
than 2 years. One of these survivors is an infant with metastatic
ATRT. There was no TRM or severe morbidity. This approach
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HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS
IN METABOLISM; A NATIONAL SURVEY IN JAPAN
Takakura, H.1, Shimizu, T.1, Tanaka, A.2, Okuyama, T.3, Kato, K.4,
Ohashi, T.5, Sakai, N.6, Mugishima, H.7, Suzuki, Y.8, Kato, S.1. 1 Tokai
University School of Medicine, Isehara, Kanagawa, Japan; 2 Osaka City
University, Osaka, Japan; 3 National Center for Child Health and Devel-
opment, Tokyo, Japan; 4 Japanese Red Cross 1st Nagoya Hospital, Nagoya,
Aichi, Japan; 5 Jikei Medical College, Tokyo, Japan; 6 Osaka University
School of Medicine, Osaka, Japan; 7 Nihon University School of Medicine,
Tokyo, Japan; 8 Gifu University School of Medicine, Gifu, Japan.
Purpose: Hematopoietic stem cell transplantation (HSCT) has
been successfully applied to some forms of inborn errors in metab-
olism (IEM). However, its long term effects have varied according
to the type and the stage of disease. Among mucopolysaccharidosis
(MPS), the efficacy of HSCT in type II (Hunter’s disease) has been
controversial.
A nationwide survey was performed to collect data on transplant
outcomes and long term clinical effects in HSCT for IEM in Japan,
in order to clarify the problems and the efficacies in those diseases. A
special focus was put on Hunter’s disease, the most common form
among Asian MPS patients, and a detailed comparison was made
with patients to whom HSCT had not been applied. Patients:
Data were collected on 141 patients from 35 institutes. HSCT
were done during the period between 1985 and 2004, and the min-
imum follow-up was one year in long term survivors.
Diseases: MPS 72, adrenoleucodystrophy (ALD);38, I-cell dis-
ease;6, metachromatic leucokystrophy (MLD);7, others;14
Sex: M/F 113/28
Age at first HSCT:median 4 years old (0–15)
Donors (1st HSCT): siblings;63, parents;11, unrelated;67
HLA compatibility (1st HSCT): match;108, mismatch;32, un-
known;1
Cell sources (1st HSCT): BM;113, PB;2, CB;22 Transplant
Outcomes: Survival: alive;114 (81%), dead;27(19%)
Overall survival (OS) rates according to disease: MPS(N 5
71);87%, ALD(N 5 38);76%, Gaucher(N 5 4);75%, MLD(N 5
7);43%, I-cell(N 5 6);22%. (P 5 0.006)
OS according to donor: sibling(N 5 62);87%, UBM(N 5
48);80%, UCB(N 5 19);68%, parents(N 5 11);64%. (P 5 0.002)
OS according to HLA compatibility: match(N5 108);79%, mis-
match(N 5 32);69%. (P 5 0.008)
OS according to cell source: BM(N 5 117);79%, CB(N 5
22);58%. (P\ 0.001) Clinical Effects: Long term clinical effects
varied from disease to disease and from patient to patient. Patients
who were transplanted in early stages have benefited more than pa-
tients transplanted in advanced stages.
A comparison in Hunter’s disease between 44 transplanted pa-
tients and with untransplanted patients revealed that quality of life
improved rapidly following HSCT due to normalization in range
of joint movement, and that neurological progress could be pre-vented to some extent even in severe form. Conclusion: Our study
confirmed the efficacy of HSCT in selected patients with IEM in
early stages. A detailed comparison in Hunter’s disease with un-
transplanted patients suggested the efficacy of HSCT even in severe
form, but the neurological effect seemed to be less than that in
Hurler’s disease (MPS IH).193
OSTEONECROSIS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Vrooman, L., Duncan, C., Eaton, M., Silverman, L.B., Lehmann, L.
Dana-Farber Cancer Institute, Boston, MA.
Background: Osteonecrosis (ON) is a potentially devastating
complication of pediatric hematopoietic stem cell transplantation
(HSCT).We report the frequency of symptomatic ON in pediatric
patients (pts) who underwent allogeneic HSCT at Children’s Hos-
pital Boston/Dana-Farber Cancer Institute over a 6-year period.
Methods: We retrospectively reviewed the medical records of
293 consecutive pts who underwent 307 allogeneicHSCTs between
January 1, 2000 and December 31, 2006. Diagnosis of ON was
based on patient symptoms and confirmed by review of the attend-
ing radiologist’s final reading of at least one radiographic study.Re-
sults: A total of 15 pts (5.1%) developed symptomatic ON.
Underlying diagnoses included 5 pts with acute lymphoblastic lym-
phoma (ALL), 3 acute myeloid leukemia, 1 myelodysplastic syn-
drome, 3 chronic myeloid leukemia, 2 aplastic anemia, and 1
sickle cell disease. Eleven pts underwent unrelated donor HSCT
and 4 had matched sibling transplants. Eleven pts (73%) were
$10 years of age at the time of HSCT. Thirteen (87%) developed
chronic graft-versus-host disease (GVHD), 9 of whom received ste-
roids for over 12 months. The 2 pts without chronic GVHD had an
underlying diagnosis of ALL. Two pts underwent a second alloge-
neic HSCT for relapsed disease and developed ON only after the
second transplant. One pt was diagnosed w/ON prior to HSCT
with ON that worsened significantly post HSCT. With regard to
sites of ON, only 2 pts had a single site (unilateral hip and unilateral
knee). Six pts developed bilateral ONof the hips. Of these, 2 pts also
had bilateral knee ON (one also with ON of the sacrum). Five ad-
ditional pts developed bilateral ONof the knees and 2 pts developed
bilateral ON of the ankles. Two pts underwent surgical interven-
tions; 1 pt underwent core decompression for bilateral knee ON,
and the other, arthroscopy with debridement and drilling of the ta-
lus for extensive ankle involvement. Eight of the 15 pts are currently
surviving. Four pts are known to have persistent complaints of joint
pain.Conclusion: Symptomatic ON developed in 5.1% of pts who
underwent allogeneicHSCT. Themajority of pts with ONwere af-
fected at multiple sites. Further interventional and follow-up studies
aimed at identifying those at greatest risk, preventing the complica-
tion, and decreasing morbidity fromON are needed in the pediatric
HSCT population.194
INTRAVENOUS BUSULFAN IN CHILDREN PRIOR TO HAEMATOLOGICAL
STEM CELL TRANSPLANTATION, HOW NARROW IS THE THERAPEUTIC
WINDOW?
Bartelink, I.H.1, Bredius, R.G.M.2, Egberts, T.C.G.1, Suttorp, M.M.2,
Bierings, M.1, Knibbe, C.3,4, Zwaveling, J.2, Boelens, J.J.1. 1 UMCU,
Utrecht, Netherlands; 2 LUMC, Leiden, Netherlands; 3 Antonius Hospi-
tal, Nieuwegein, Netherlands; 4 Leiden/Amsterdan Center for Drug Re-
search, Leiden University, Leiden, Netherlands.
Background: A high dose of busulfan (BU) combined with ther-
apeutic drug monitoring as been suggested to be associated with
higher event free survival (EFS) rates due to less graft-failure/re-
lapses and lower toxicity. Since 2001 we (LUMC and UMCU)
are using intravenous BU in various myelo-ablative regimen: we
have targeted to various area’s under the curve (AUC) and have
given BU either once daily or 4 times a day. In this study we retro-
spectively analysed the association between busulfan exposure
72 Poster Session Iexpressed as AUC and outcome. Methods: All children, trans-
planted between 2001–2006, receiving intravenous BU as part
of a myeloablative regimen, from whom AUC measurements
were available, were included. Patients were separated into five
percentiles based on total AUC. The association with the primary
endpoints EFS (event defined as dead, graft-failure or relapse)
and survival as well as the secondary endpoints (acute Graft-ver-
sus-Host Disease grade 2–4; aGvHD, and Veno-occlusive Dis-
ease: VOD) were tested using uni- and multivariate Cox
regression analysis. The lowest AUC group was used as index
group. Results: 102 patients were included (46 malignant indica-
tions; 56 non-malignant indications). Median age at transplantation
was 3.1 years (range 0.2 to 21 years). The overall EFS and survival
were 68% and 72% respectively. In multivariate analyses a total
AUC between 72,500–80,000mgh/l was associated with highest
EFS (85%, p 5 0.029, table). Other factors influencing EFS were
HLA-disparity and age at SCT. Similar associations were found
for survival. aGvHD occurred in 16% of patients and was most fre-
quently seen in the highest AUC group 35% (p 5 0.041, table).
VOD was noted more frequent in the higher AUC, but not signif-
icant (p 5 0.164). The once daily dosing versus 4-times daily did
not influence any of the results. Above an AUC of 72.500 mgh/l,
no graft-failure was note and only 2 relapses (11%) were note.
While under 72.500 mgh/l, 9 graft-failure and relapses were seen
(31%).
In conclusion a total AUC between 72,500–80,000 mgh/l is as-
sociated with highest EFS in malignants as well as in non-malignant
disease. Higher AUC was associated with more toxicity negatively
influencing EFS, while lower AUC was associated with more re-
lapse/graft failure. Once daily dosing might be a practical alterna-
tive to 4-times daily. Dosing of busulfan in children should be
targeted by therapeutic drug monitoring to a small therapeutic
range to improve EFS.
Multivariate analysis of primary and secondary endpoint: EFS en GvHD
EFS GvHDP HR CI-95% P OR CI-95%AUC 0–55.000 1 1AUC 55,000–65,000 0.320 0.60 0.22–1.64 0.920 0.86 0.05–15.8AUC 65,000–72,500 0.537 0.72 0.25–2.05 0.330 3.41 0.29–40.2AUC 72,500–80,000 0.029 0.20 0.05–0.85 0.177 5.58 0.46–67.7AUC 80,000–120,000 0.378 0.59 0.18–1.92 0.041 12.55 1.10–143Malign vs
non-malignant0.080 5.13 0.82–31.9HLA disparity 0.001 3.79 1.72–8.35 0.197 0.38 0.09–1.65Melphalan 0.541 1.71 0.31–9.43Sero-therapy 0.244 2.42 0.55–10.7Age 0.001 1.12 1.05–1.19195
INFLUENCE OF DONOR AGE ON RISK OF CHRONIC GVHD IN SEX-MIS-
MATCHED PEDIATRIC ALLOGENIC HEMATOPOIETIC STEM CELL TRANS-
PLANT
Friedrich-Medina, P.M.2, Duncan, C.N.1, Lehmann, L.E.1. 1 Dana
Farber Cancer Institute/Children’s Hospital Boston, Boston, MA; 2 Chil-
dren’s Hospital Boston, Boston, MA.
Background:Donor age, donor/recipient sex mismatch, and do-
nor parity are considered to be significant risk factors for the devel-
opment of acute and chronic graft versus host disease. Most reports
indicate that female donors into male (F-M) recipients confer the
greatest risk. Female donor alloimmunization to minor histocom-
patibility antigens encoded by the Y-chromosome is thought to de-
velop through sexual exposure and/or parity and at least partially
explain the increased risk of GVHD seen in F-M transplants. There
are no studies that evaluate this association when a young female
serves as donor. Methods: Data from 43 male to male (M-M) and
38 female to male (F-M) sibling donor hematopoietic transplants
performed at our institution from 1998–2006 was collected and an-
alyzed. Twenty three F-M transplants used female donors less or
equal to 12 years old. Age range and mean age for each group wasas follows: M-M (1–23 years, 11 years), F-M with donor less than
or equal to 12 years old (0.2–16 years, 7 years), and F-Mwith donor
over 12 years old (9–33 years, 15 years). The majority of patients in
both groups had hematologic malignancies, was fully matched, and
received Cyclosporine and Methotrexate as GVHD prophylaxis.
Outcomes between patients with female donors less or equal to
12 years old were compared to those of patients with female donors
more than 12 years old, using patients withM-M transplant as base-
line. Only patients with aGVHD grade II-IV were included in anal-
ysis. Patients with death in the first 100 days were not included in
the cGVHD analysis.Results:As reported from adult literature, in-
creased risk of chronic GVHD (RR5 3.3, 95%CI5 1.47–7.38, p5
0.006) was observed in F-M transplant from older female donor
when compared toM-M (RR5 1).However, no significant increase
in risk of acute or chronic GVHD (RR5 0.76, p5 0.5; RR5 0.93,
p 5 0.9) was observed when the subgroup including young female
donors was compared to M-M (RR 5 1). Furthermore, no signifi-
cant difference in relapse or transplant related mortality rates in
the first 100 days were observed. Conclusion: This data suggests
that the increased risk for chronic GVHD observed in adult sex-
mismatched allogenic transplants may be related to donor alloim-
munity and may not be present when a young female serves as
donor.
Effect of donor-recipient sex match on Grade II-IV aGVHD, cGVHD,
Disease Relapse and Death in first 100 days
RR 95% CI P valueaGVHD
M-M (n 5 43) 11 1 NA NA
F-M (all combined) 10 1.02 0.60–1.72 0.93
F-M\12 (n 5 23) 4 0.76 0.29–1.78 0.5
F-M .13 (n 5 15) 6 1.61 0.68–3.82 0.29cGVHD
M-M (n 5 40) 4 1 NA NA
F-M (all combined) 8 1.52 0.93–2.48 0.14
F-M\12 (n 5 22) 2 0.93 0.28–3.05 0.9
F-M .13 (n 5 14) 6 3.3 1.47–7.38 0.006Relapse
M-M (n 5 43) 12 1 NA NA
F-M\12 (n 5 23) 4 0.65 0.26–1.65 0.34
F-M .13 (n 5 15) 4 0.95 0.35–2.57 0.92Death
M-M (n 5 43) 3 1 NA NA
F-M\12 (n 5 23) 1 0.7 0.12–3.97 0.7
F-M .13 (n 5 15) 1 0.92 0.16–5.58 0.97NA5 Not applicable.196
ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN UNRELATED CORD
BLOOD TRANSPLANTATION (UCBT): SINGLE INSTITUTION EXPERI-
ENCE, JULY 1996 – JUNE 2007
Alsultan, A., Giller, R.H., Bathurst, J., Hild, E., Kissane, B., Gore, L.,
Foreman, N.K., Keating, A., Quinones, R.R. The Children’s Hospital
and the University of Colorado School of Medicine, Aurora, CO.
UCBT has been associated with a lower incidence of GVHD
when compared to unrelated transplant using adult donors. How-
ever, the characteristics (sites, time to onset, course, and tolerability)
of GVH followingUCBThas not been as clearly elucidated.We re-
view GVH in 81 consecutive UCBT treated on a single therapeutic
trial with consistenet GVH prophylaxis. 13 patients were unevalu-
able based on death prior to UCB infusion (2), death prior to en-
graftment (7), or graft rejection (4). Thus, 68 patients were
evaluable for AGVHD (41 male, 27 female; median age 6.8 yr
(range, 0.3–24.4 yr); median weight 22 Kg (range, 5.35–82.9 Kg)).
Diagnoses included leukemia in 75% (63% ALL, 25% AML,
12% CML or JMML), MDS 3%, lymphoma 1%, metabolic disor-
ders 6%, immune/genetic disorders 9%, and aplastic anemia 6%.
Acute leukemia disease status at UCBT was CR1 24%, CR2
